NanoPass Technologies, a company specializing in intradermal delivery solutions, secured a $6 million funding round, from which, lead investor Awz Ventures invested $4 million. The investment aims to support NanoPass’s commercial expansion and innovation efforts.
Daniel Levitats, with over 25 years of experience in high-tech and medical device companies, has been appointed as the new CEO to lead the company’s growth initiatives.
The company’s flagship product is the MicronJet™ platform, which utilizes Micro Electro Mechanical Systems (MEMS) technology for intradermal delivery. The platform features a proprietary pure silicon crystal-made hollow pyramid structure, which is FDA-cleared for intradermal delivery and is smaller than 1 mm in size. MicronJet™ has been clinically proven to provide high delivery consistency, low leakage rates, and high success rates in over 70 clinical studies.
The MicronJet™ platform is designed to optimize product delivery performance in both therapeutic and aesthetic procedures. It offers precision, consistency, and safety that surpasses traditional injection methods. The near-painless nature of the delivery system has made it a preferred choice for clinicians and patients worldwide.
Awz Ventures’ investment in NanoPass is part of its Active Capital strategy, which provides multi-stage investment, mentorship, access to strategic partnerships, and preparation for future funding rounds and M&A opportunities.
NanoPass Technologies was founded in 2000 by Dr. Shuki Yeshurun. Awz Ventures join others investors in the company, including Ofer Hi Tech, D Partners, WFD Ventures, and Elcam Medical. The company’s products are available globally and protected by a robust patent portfolio.
